No Data
No Data
NEW RAY MEDIC: SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORTFOR THE YEAR ENDED 31 DECEMBER 2023
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
New Ray Medicine Shareholders to Vote July 16 on Purchase Contract
Xinrui Pharmaceutical (06108.HK) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group
Gelonghui, May 30, 丨 Xinrui Pharmaceutical (06108.HK) announced that on May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company, as an investor) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group, CITIC Securities (Hong Kong) Limited (as the sole sponsor) and CITIC Lyon Securities Limited (as the sole sponsor and overall coordinator). Based on this, China Xinrui has agreed to subscribe for investors' shares at the sale price. The total investment in investors' shares is HK$12 million (excluding brokerage commissions and levies that China Emerging Companies will pay on investors' shares).
No Data